Assay Detail
ADMET
CHEMBL1780917
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of CYP3A4
3
Total Activities
3
Compounds Tested
3
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | ADMET |
| Confidence | 8 — Homologous single protein target |
| Curated By | Autocuration |
Publication
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| Inhibition | 1 | - | - |
| IC50 | 1 | 5.97 | 5.97 |
| INH | 1 | - | - |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL1779699 | — | — | 1 | 5.97 |
| CHEMBL1779705 | — | — | 1 | - |
| CHEMBL1779710 | EVOGLIPTIN | 4.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL1779699 | — | IC50 | = | 1075.0 | nM | 5.97 |
| CHEMBL1779705 | — | Inhibition | - | % | - | |
| CHEMBL1779710 | EVOGLIPTIN | INH | > | 50.0 | uM | - |